Hims & Hers Pauses Compounded Wegovy Sales After FDA Probe
- Has halted plans to market a compounded version of Novo Nordisk’s weight loss drug, Wegovy, following scrutiny from health officials and a request for a Department of Justice...
- Hims & Hers initially offered the compounded drug at $49 per month, significantly undercutting the price of Wegovy, which ranges from $149 to $299 monthly.
- The Food and Drug Administration (FDA) signaled its intent to intervene, stating it would take “decisive steps” against companies marketing unapproved, compounded versions of GLP-1 drugs, the class...
Hims & Hers Health, Inc. Has halted plans to market a compounded version of Novo Nordisk’s weight loss drug, Wegovy, following scrutiny from health officials and a request for a Department of Justice investigation. The company announced its decision on , just days after launching the lower-cost alternative.
Hims & Hers initially offered the compounded drug at $49 per month, significantly undercutting the price of Wegovy, which ranges from $149 to $299 monthly. Novo Nordisk’s Wegovy is the oral formulation of their previously released injectable weight loss medication. The move by Hims & Hers drew immediate criticism, as the mass production of compounded drugs is generally permitted only when the original brand-name medication is in shortage – a condition that does not currently exist for Wegovy.
The Food and Drug Administration (FDA) signaled its intent to intervene, stating it would take “decisive steps” against companies marketing unapproved, compounded versions of GLP-1 drugs, the class of medications to which Wegovy belongs. This was followed by a request from the Department of Health and Human Services (HHS) to the Department of Justice (DOJ) on , to investigate Hims & Hers for potential violations of federal law.
Compounding pharmacies are permitted to create customized medications for individual patients based on a licensed physician’s prescription. However, they are not authorized to mass-produce and market drugs as a substitute for commercially available, FDA-approved medications. The concern raised by health officials centers on the potential safety risks associated with unapproved compounded drugs, including variations in ingredient quality, dosage accuracy, and sterility.
GLP-1 receptor agonists, like Wegovy, work by mimicking the effects of the naturally occurring GLP-1 hormone, which regulates appetite and food intake. These medications have demonstrated significant efficacy in promoting weight loss when combined with lifestyle modifications, such as diet and exercise. The FDA approval of Wegovy marked a significant advancement in obesity treatment, offering a new option for individuals struggling with this chronic health condition.
The situation highlights the growing demand for effective weight loss treatments and the challenges of ensuring patient safety in the face of increasing market pressures. The availability of a lower-cost alternative, even one produced through compounding, can be appealing to patients who may otherwise be unable to afford the branded medication. However, regulatory agencies emphasize the importance of prioritizing patient safety and adhering to established pharmaceutical standards.
BofA Securities maintains an underperform rating on Hims & Hers Health, Inc. (HIMS), according to recent reports. The company’s stock has experienced volatility in recent days, tumbling 7% following the launch and subsequent withdrawal of the compounded Wegovy alternative. Investor attention has been focused on the implications of this situation for Hims & Hers’ business model and future growth prospects.
The launch of oral Wegovy itself has been met with positive attention, prompting questions about the potential for increased investment in Novo Nordisk stock. The strong launch suggests a significant market appetite for a convenient, oral formulation of this effective weight loss medication.
This incident serves as a reminder of the complex interplay between pharmaceutical innovation, regulatory oversight, and patient access. While competition and affordability are important considerations, maintaining the integrity of the drug supply and ensuring patient safety remain paramount. The DOJ investigation will likely focus on whether Hims & Hers’ actions constituted a violation of federal regulations governing the compounding and distribution of pharmaceutical products.
Patients considering weight loss medications should consult with their healthcare provider to discuss the risks and benefits of available treatment options and to ensure they receive safe and effective care. This proves crucial to obtain medications from reputable sources and to follow the guidance of a qualified medical professional.